Sanofi (SAN) Stock Analysis
Sanofi is a multinational pharmaceutical company engaged in research, development, manufacturing, and marketing of therapeutic solutions across immunology, rare diseases, neurology, oncology, and vaccines. Investors research Sanofi for exposure to diversified pharmaceutical pipelines, established vaccine franchises, and strategic collaborations with biotech firms in emerging treatment areas.
Get a full AI research report on SAN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Sanofi do?
Sanofi generates revenue through multiple therapeutic segments: immunology and inflammation treatments, rare disease therapies, neurological medications, oncology drugs, and an extensive vaccine portfolio including pediatric combinations, respiratory syncytial virus protection, and seasonal flu vaccines. The company monetizes its pipeline through internal development and commercialization as well as strategic partnerships with biotech firms like Exscientia, ABL Bio, and Kymera Therapeutics, which provide access to novel small-molecule and protein degrader therapies. Its gross margin of 73.5% reflects typical pharmaceutical pricing power, while operating margin of 21% demonstrates operational efficiency across manufacturing and distribution.
Bull case
- ✓Diversified revenue streams across vaccines, immunology, rare diseases, and oncology reduce dependency on single therapeutic area performance.
- ✓Strong gross margin of 73.5% and operating margin of 21% indicate pricing power and operational leverage typical of established pharmaceutical manufacturers.
- ✓Forward P/E ratio of 8.3 suggests the market prices in modest near-term earnings growth, potentially offering valuation appeal relative to the current P/E of 23.2.
- ✓Strategic collaborations with AI-driven drug discovery platforms (Atomwise, Insilico Medicine) and protein degradation specialists position the company in emerging therapeutic modalities.
- ✓Dividend yield of 5.54% provides current income, though the payout ratio of 127% indicates the company is returning more than net income to shareholders.
Bear case
- ✗Current ratio of 0.987 and quick ratio of 0.487 suggest tight short-term liquidity, with current liabilities exceeding current assets.
- ✗Debt-to-equity ratio of 33.89 indicates substantial leverage, which may constrain financial flexibility during downturns or for major acquisitions.
- ✗PEG ratio of 28.73 appears elevated relative to forward growth expectations, potentially signaling valuation concerns if earnings growth disappoints.
- ✗Return on equity of 5.71% and return on assets of 5.09% are modest, suggesting the company generates limited profit per unit of shareholder capital deployed.
- ✗Payout ratio exceeding 100% is unsustainable long-term and may pressure dividend coverage if earnings decline or cash flow weakens.
SAN valuation & financial health
Sanofi trades at a current P/E of 23.2 but a forward P/E of 8.3, implying market expectations of significant earnings growth or one-time items in trailing results. The company's 73.5% gross margin reflects pharmaceutical pricing strength, but ROE of 5.71% and ROA of 5.09% are relatively low for a large-cap pharma firm, suggesting capital efficiency challenges. The debt-to-equity ratio of 33.89 and current ratio below 1.0 indicate a leveraged balance sheet with near-term liquidity constraints, while the 5.54% dividend yield supported by a 127% payout ratio raises questions about dividend sustainability without earnings growth or asset sales.
The bottom line
Sanofi presents a mixed financial profile typical of mature pharmaceutical companies: established market positions and strong margins offset by leverage, tight liquidity, and modest returns on capital. The forward P/E of 8.3 versus current P/E of 23.2 suggests the market is pricing in either near-term earnings recovery or accounting normalization, which warrants scrutiny of upcoming guidance and pipeline progress. Key factors to monitor include cash flow generation relative to the unsustainable dividend payout ratio, progress on clinical trials from biotech partnerships, and whether the company can improve capital efficiency and reduce leverage. Investors should assess whether the valuation and dividend yield compensate for balance sheet risks and modest profitability metrics relative to peers.
Frequently asked questions
What does Sanofi do?
Sanofi is a pharmaceutical company that researches, develops, manufactures, and sells medicines and vaccines across immunology, rare diseases, neurology, oncology, and pediatric/adult vaccines. It operates globally and partners with biotech firms to access emerging therapies in areas like protein degradation and AI-driven drug discovery.
Is Sanofi profitable?
Yes, Sanofi is profitable with a net margin of 8.09% and operating margin of 21%, indicating the company generates earnings from operations and net income. However, ROE of 5.71% and ROA of 5.09% suggest modest returns relative to capital employed.
What is Sanofi's dividend yield?
Sanofi's dividend yield is 5.54%, making it attractive for income-focused investors. However, the payout ratio of 127% means the company is distributing more than net income, raising questions about long-term sustainability without earnings growth.
Is Sanofi overvalued or undervalued?
Sanofi's valuation is mixed: the current P/E of 23.2 appears elevated, but the forward P/E of 8.3 suggests the market expects significant earnings growth ahead. The PEG ratio of 28.73 is high relative to typical growth rates, warranting evaluation of pipeline catalysts and earnings guidance.
What are the main risks for Sanofi investors?
Key risks include tight liquidity (current ratio 0.987), high leverage (debt-to-equity 33.89), an unsustainable dividend payout ratio above 100%, and modest returns on capital. Additionally, pharmaceutical companies face regulatory, patent expiration, and clinical trial risks.
Does Sanofi have a strong balance sheet?
Sanofi's balance sheet shows signs of stress: the current ratio below 1.0 and quick ratio of 0.487 indicate short-term liquidity pressure, while debt-to-equity of 33.89 reflects substantial leverage. These metrics suggest limited financial flexibility compared to lower-leveraged peers.
Research SAN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.